Abstract
A series of chromone derivatives were designed as potential topoisomerase I (Top I) inhibitors based on the docking simulation study. Sixteen synthesized compounds were evaluated for Top I inhibitory activity and some compounds were further tested for in vitro cytotoxic activity. The most potent inhibitor, chromone 11b showed greater inhibitory activity (IC50 = 1.46 μM) than the known Top I inhibitors, i.e., camptothecin, fisetin and morin, but inactive against breast cancer cell (MCF-7), oral cavity cancer cell (KB) and small cell lung cancer (NCI-H187). Chromone 11c, another potent inhibitor (IC50 = 6.16 μM), exhibited cytotoxic activity against KB (IC50 = 73.32 μM) and NCI-H187 (IC50 = 36.79 μM).
Keywords: Chromone derivatives, topoisomerase I inhibitory activity, cytotoxic activity, enzymes, DNA, flavonoids, hydrogen bonds, melting points, dimethylsulfoxide, chromatography
Medicinal Chemistry
Title:Synthesis, Topoisomerase I Inhibitory and Cytotoxic Activities of Chromone Derivatives
Volume: 9 Issue: 3
Author(s): Chirattikan Maicheen, Jiraphun Jittikoon, Opa Vajragupta and Jiraporn Ungwitayatorn
Affiliation:
Keywords: Chromone derivatives, topoisomerase I inhibitory activity, cytotoxic activity, enzymes, DNA, flavonoids, hydrogen bonds, melting points, dimethylsulfoxide, chromatography
Abstract: A series of chromone derivatives were designed as potential topoisomerase I (Top I) inhibitors based on the docking simulation study. Sixteen synthesized compounds were evaluated for Top I inhibitory activity and some compounds were further tested for in vitro cytotoxic activity. The most potent inhibitor, chromone 11b showed greater inhibitory activity (IC50 = 1.46 μM) than the known Top I inhibitors, i.e., camptothecin, fisetin and morin, but inactive against breast cancer cell (MCF-7), oral cavity cancer cell (KB) and small cell lung cancer (NCI-H187). Chromone 11c, another potent inhibitor (IC50 = 6.16 μM), exhibited cytotoxic activity against KB (IC50 = 73.32 μM) and NCI-H187 (IC50 = 36.79 μM).
Export Options
About this article
Cite this article as:
Maicheen Chirattikan, Jittikoon Jiraphun, Vajragupta Opa and Ungwitayatorn Jiraporn, Synthesis, Topoisomerase I Inhibitory and Cytotoxic Activities of Chromone Derivatives, Medicinal Chemistry 2013; 9 (3) . https://dx.doi.org/10.2174/1573406411309030003
DOI https://dx.doi.org/10.2174/1573406411309030003 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dibenzofurans from Lichens – A Pharmacological Overview
Current Topics in Medicinal Chemistry The Role of Bax/Bcl-2 and Pro-Caspase Peptides in Hypoxia/Reperfusion-Dependent Regulation of MAPKERK: Discordant Proteomic Effect of MAPKp38
Protein & Peptide Letters Cannabinoids, Immune System and Cytokine Network
Current Pharmaceutical Design Bortezomib Enhances the Antitumor Effects of Interferon-β Gene Transfer on Melanoma Cells
Anti-Cancer Agents in Medicinal Chemistry Will it Ever Become Possible to Prevent Dopaminergic Neuronal Degeneration?
CNS & Neurological Disorders - Drug Targets KCa3.1 Channel Modulators as Potential Therapeutic Compounds for Glioblastoma
Current Neuropharmacology Pharmacological Interference With Protein-protein Interactions of Akinase Anchoring Proteins as a Strategy for the Treatment of Disease
Current Drug Targets Targeting Lipoxygenases (LOs): Drug Design And Discovery
Current Enzyme Inhibition Pre-clinical Efficacy and Safety Pharmacology of PEGylated Recombinant Human Endostatin
Current Molecular Medicine Novel and Emerging Drugs for Acute Lymphoblastic Leukemia
Current Cancer Drug Targets Microwave-assisted Cycloaddition Reactions in Carbo- and Heterocyclic Chemistry
Current Organic Chemistry Recent Advances in the Synthesis and Development of Curcumin, its Combinations and Formulations and Curcumin-like Compounds as Anti-infective Agents
Current Medicinal Chemistry Purification and Biological Evaluation of Some Bioactive Metabolomics as Antimicrobial Agent
Letters in Drug Design & Discovery Flavonoids in Atherosclerosis: An Overview of Their Mechanisms of Action
Current Medicinal Chemistry Emerging Insight into MAPK Inhibitors and Immunotherapy in Colorectal Cancer
Current Medicinal Chemistry Current Cannabidiol Safety: A Review
Current Drug Safety Gedunin, A Neem Limonoid in Combination with Epalrestat Inhibits Cancer Hallmarks by Attenuating Aldose Reductase-Driven Oncogenic Signaling in SCC131 Oral Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Chlorambucil Cytotoxicity Reduction in Rats Through Bone Marrow, An In vivo Study
Anti-Cancer Agents in Medicinal Chemistry The True Face of the Revolution in Oncology Drug Development: A Personal Reflection
Current Clinical Pharmacology MUC1 Story: Great Expectations, Disappointments and the Renaissance
Current Medicinal Chemistry